

AV

(19)  **Europäisches Patentamt**
European Patent Office
Office européen des brevets



(11) **EP 1 146 054 A1**

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

(43) Date of publication:
17.10.2001 Bulletin 2001/42

(21) Application number: **99973038.5**

(22) Date of filing: **02.12.1999**

(51) Int Cl.⁷: **C07K 14/47**, C12N 15/12,
C12N 5/10, C12P 21/02,
C07K 16/18, C12P 21/08
// C12N15:12, C12R1:91,
C12N5:10, C12R1:91,
C12P21:02, C12R1:91

(86) International application number:
PCT/JP99/06753

(87) International publication number:
WO 00/32628 (08.06.2000 Gazette 2000/23)

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **03.12.1998 JP 34403898**

(71) Applicant: **ONO PHARMACEUTICAL CO., LTD.**
Osaka-shi, Osaka 541-8526 (JP)

(72) Inventor: **OKAMOTO, Takashi**
Nagoya-shi, Aichi 467-0041 (JP)

(54) **RelA BINDING INHIBITOR, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF**

(57) Human RelA-associated inhibitor (RAI) comprising 351 amino acid, process for producing it, cDNA encoding it, fragment capable of hybridizing selectively to the cDNA sequence, plasmid for expression and duplication comprising the cDNA, host cell transformed with the plasmid, antibody against the polypeptide,

pharmaceutical composition comprising the polypeptide or the antibody against it and method for diagnosis of diseases using the antibody against the RAI.

RAI of the invention is capable of binding to p65, which is a subunit of transcription factor NFκB, therefore, it is thought to be useful for treatment and/or prevention of various diseases.

EP 1 146 054 A1

Description**Technical Field**

- 5 [0001] The present invention relates to a protein that inhibits activation of transcription factor NF κ B.
- [0002] More detailed, the present invention relates to p65-binding protein (called RelA-associated inhibitor or abbreviated as RAI hereinafter) that binds to p65, which is a subunit of transcription factor NF κ B, and that inhibits transcriptional activity of NF κ B, a process for producing it, a cDNA encoding it, a vector comprising the cDNA, a host cell transformed with the vector, an antibody against the inhibitor, and a pharmaceutical composition comprising the inhibitor
- 10 or the antibody.
- [0003] Further, the present invention relates to recombinant production of these proteins (especially, in vivo production), a nucleotide encoding them, a vector for expression and duplication and treatment and/or prevention of adult respiratory distress syndrome (ARDS), asthma, Allograft rejection, inflammatory diseases (inflammatory arthritis, angitis etc.), ischemic diseases, autoimmune diseases including chronic rheumatism, metastasis and invasion of cancer, vasoconstriction and diseases induced by NF κ B besides above.
- 15

Technical Background

- [0004] An acceleration of expressing many and various genes is observed in inflammation. Such genes include ones encoding interleukin, transcription factors, cohesive molecules, and factors in coagulation system etc. NF κ B which is a transcription factor has been said to relate to the transcription of such genes mostly.
- [0005] It has been known that transcription factor NF κ B is expressed in cytoplasm. The transcription and induction of gene due to NF κ B-like proteins have been identified in a lot of cells, so it is shown that such a factor
- 25 possible to translocate the transcription factor prepared in advance from cytoplasm to nucleus.
- [0006] It is known that this translocation is controlled by phosphorylation and degradation of suppressor protein which is called for I κ B.
- [0007] Transcription factor NF κ B was isolated from matured B cells in the form of binding to 10 nucleotide sequence motif in κ light chain enhancer for the first time. Therefore, NF κ B was thought to be specific for the generating stage of matured B cells. However, NF κ B-like proteins have been identified in a lot of cells, so it is shown that such a factor
- 30 relates to induction of gene transcription generally. Such fact has been confirmed by functional identification of an active type NF κ B-binding position in some inducing genes.
- [0008] NF κ B is a heterodimer consisting of a subunit of 50 kDa (p50) and a subunit of 65 kDa (p65).
- [0009] NF kappa B (NF κ B), which is a nuclear factor, is a sequence-specific DNA-binding protein complex which regulates the expression of viral genomes, including the human immunodeficiency virus (HIV), and a variety of cellular
- 35 genes, particularly those involved in immune and inflammatory responses. The members of the NF κ B family in mammalian cells include the proto-oncogene c-Rel, p50/p105 (NF κ B1), p65 (RelA), p52/p100 (NF κ B2), and RelB etc.
- [0010] All of these proteins share a conserved 300 amino acid region of homology known as the Rel homology domain (RHD), which is responsible for DNA binding, dimerization, and nuclear translocation of NF κ B.
- [0011] In most cells, Rel family members can form hetero- and homodimers with distinct specificities in various combinations. A common feature of the regulation of transcription factors belonging to Rel family is their sequestration in the cytoplasm as inactive complexes with a class of inhibitory molecules known as IKBs. Treatment of cells with a variety of inducers such as phorbol esters, interleukin 1, tumor necrosis factor- α (TNF- α), viral infection and many mitogens and cytokines etc. results in the dissociation of the cytoplasmic complexes and translocation of free NF κ B
- 40 into the nucleus. The dissociation of the cytoplasmic complexes is known to be triggered by the phosphorylation and subsequent degradation of the IKB proteins. Such a degradation exposes the nuclear localization sequence in the remaining NF κ B heterodimer, leading to nuclear translocation and subsequent binding of NF κ B to DNA regulatory elements within NF κ B target genes. The p65 subunit is frequently detected in NF κ B complexes and has a strong transcription activation potential. p65 dimerizes with other NF κ B family members and activates gene expression via its potent transactivation domain.
- 45
- 50

Disclosure of the Invention

- [0012] The object of the present invention is to provide a novel protein that inhibits transcriptional activity of NF κ B (NF κ B inhibitor), a process for producing it, a cDNA encoding it, a vector comprising the cDNA, a host cell transformed with the vector, an antibody against the inhibitor, and a pharmaceutical composition comprising the inhibitor or the
- 55 antibody.
- [0013] The present inventor et al. have thought that novel inhibitors may exist besides I κ B which was known as an NF κ B inhibitor. From the result of focusing their attention on and an extensive studies of NF κ B, especially p65 subunit,

the present inventor et al. have achieved to find out a novel NF κ B inhibitor, confirmed amino acid sequence, a cDNA sequence encoding it, function of the inhibitor and tissue-distribution etc. and then completed the present invention.

[0014] RelA-associated inhibitor of the present invention is regarded as nucleus factor and inhibits NF κ B-dependent transcription activation by inhibiting DNA-binding activity of NF κ B. The gene encodes RelA-associated inhibitor is a gene having a high homology to the C-terminal region of 53BP2 containing four consecutive ankyrin repeats and an SH3 domain.

[0015] RAI appeared to locate in nucleus with the same location pattern of TNF- α -induced p65. In addition, RAI inhibits activation of NF κ B, but does not show any influence on p53-dependent transcription activation in the cells which is transformed temporarily. Therefore, RAI is a novel p65-binding protein which relates to another mechanism of NF κ B-dependent transcription regulation. The present inventor has confirmed these interaction in vitro with bacterially expressed fusion proteins and in vivo using immunoprecipitation/ Western blot assay.

[0016] In spite of its similarity to 53BP2, RAI did not shown any interaction with p53 in a yeast two-hybrid assay. The cDNA encodes this protein has a high structural homology to 200 amino acid at the C-terminal region of 53BP2 containing four ankyrin repeats and an SH3 domain that are important for protein-protein interactions.

[0017] In human, mRNA of RAI was specifically expressed in heart, placenta and prostate while it was markedly reduced in liver, skeletal muscle and peripheral blood leukocyte.

[0018] Recent rapid developments in techniques for constructing cDNAs and sequencing techniques have made it possible to quickly sequence a large amount of cDNAs. By utilizing these techniques, a process, which comprises constructing cDNAs library from various cells or tissues, cloning cDNAs at random, identifying the nucleotide sequences thereof, expressing novel polypeptides encoded by them to analyze its physiological function, is now in progress. Method of yeast two-hybridization has been known as one of such techniques.

[0019] By this technique, it becomes possible to identify a large amount of homologous proteins at the same time and to obtain the aimed protein only easily by inserting reporter genes such as fluorescent marker etc.

[0020] The present inventor has carried out experiments of such a yeast two-hybrid screen using NF κ B protein submit p65 as a probe to find a novel factor that binds to a novel p65 and that inhibits an activity of p65 and then found out the factor of the present invention.

[0021] The sequence of RelA-associated inhibitor of the present invention has been confirmed to be novel according to a homology search. Only a sequence of RelA-associated inhibitor of the present invention is a novel one among some clones obtained by the process for the sequence of the present invention described hereinafter.

[0022] The amino acid sequence of RelA-associated inhibitor of the present invention is as shown in SEQ ID NO. 1. This amino acid sequence contains four ankyrin repeats and an SH3 domain, so it is regarded as a member of Rel family.

[0023] The present invention relates to

- (1) a RelA-associated inhibitor comprising amino acid sequence shown in SEQ ID NO. 1,
- (2) a cDNA encoding the RelA-associated inhibitor described above (1),
- (3) a cDNA comprising a nucleotide sequence shown in SEQ ID NO. 2, and
- (4) a cDNA comprising a nucleotide sequence shown in SEQ ID NO. 3.

Brief Description of Figures

[0024] Fig. 1 shows the results of analyses of GST and GST-RAI fusion proteins, which were expressed in E. coli, on SDS-PAGE with CBB staining (lanes 1 and 2) and analyses of the said proteins by autoradiography after spotting labeled p65 (lanes 3 - 5). One tenth of amount of labeled p65 at lane 5 was used at lane 3.

[0025] Fig. 2 shows the results of Northern blot analyses of RAI mRNA expression in human multiple tissues. The lower shows an amount of β -actin expression.

[0026] Fig. 3 shows a dose-dependent inhibition manner of RAI on NF κ B-dependent transcription activation. The activity of activating p65-induced transcription in case of non-expression of RAI is represented by luciferase activity at lane 9. Such an action is inhibited by RAI expression in a dose-dependent manner (lane 11, lanes 13 and 15).

Detailed Description of the Invention

[0027] The present invention relates to a RelA-associated inhibitor comprising an amino acid sequence shown in SEQ ID NO. 1 in substantially purified form, a homologue thereof, a fragment of the sequence and a homologue of the fragment.

[0028] Further, the present invention relates to cDNAs encoding the above RelA-associated inhibitor. More particularly, the present invention relates to cDNAs comprising nucleotide sequences shown in SEQ ID NOS. 2 or 3 and cDNA containing a fragment capable of hybridizing selectively to nucleotide sequences shown in SEQ ID NOS. 2 or 3.

[0029] A RelA-associated inhibitor of the present invention comprising an amino acid sequence shown in SEQ ID NO. 1 in substantially purified form will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is that of the SEQ ID NO. 1.

[0030] A homologue of RelA-associated inhibitor of the present invention comprising an amino acid sequence shown in SEQ ID NO. 1 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the polypeptide comprising the said amino acid sequence over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 more contiguous amino acids. Such a polypeptide homologue will be referred to a RelA-associated inhibitor of the present invention.

[0031] In addition, a fragment of RelA-associated inhibitor of the present invention comprising an amino acid sequence shown in SEQ ID NO. 1 or its homologues will be at least 10, preferably at least 15, for example, 20, 25, 30, 40, 50 or 60 amino acids in length.

[0032] A cDNA capable of selectively hybridizing to the cDNA comprising nucleotide sequences shown in SEQ ID NOS. 2 or 3 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the cDNA comprising the said nucleotide sequence over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 or more contiguous nucleotides. Such a cDNA will be referred to "a cDNA of the present invention". A cDNA capable of selectively hybridizing to the cDNA also includes cohesive sequence. The condition for hybridizing is preferably stringent one.

[0033] Fragments of the cDNA comprising nucleotide sequences shown in SEQ ID NOS. 2 or 3 will be at least 10, preferably at least 15, for example, 20, 25, 30 or 40 nucleotides in length, and will be also referred to "a cDNA of the present invention" as used herein.

[0034] A further embodiment of the present invention provides replication and expression vectors carrying cDNA of the present invention. The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said cDNA and optionally a regulator of the promoter. The vector may contain one or more selectable marker genes, for example, a luciferase expression gene or an ampicillin resistance gene. The vector may be used in vitro, for example, of the production of RNA corresponding to the cDNA, or used to transfect a host cell.

[0035] A further embodiment of the present invention provides host cells transformed with the vectors for the replication and expression of the cDNA of the present invention, including the cDNA comprising nucleotide sequences shown in SEQ ID NOS. 2 or 3 or the open reading frame thereof. The cells will be chosen to be compatible with the vector and may for example, be bacterial, yeast, insect cells or mammalian cells.

[0036] A further embodiment of the present invention provides a process for producing a RelA-associated inhibitor which comprises culturing host cells of the present invention under conditions effective to express a RelA-associated inhibitor of the present invention. Preferably, in addition, such a process is carried out under conditions in which the polypeptide of the present invention is expressed and then produced from the host cells.

[0037] cDNA of the present invention may also be inserted into the vectors described above in an antisense orientation in order to prove for the production of antisense. Such antisense may be used in a method of controlling the levels of a polypeptide of the present invention in a cell.

[0038] The invention also provides monoclonal or polyclonal antibodies against a RelA-associated inhibitor of the present invention. The invention further provides a process for the production of monoclonal or polyclonal antibodies to the RelA-associated inhibitor of the present invention. Monoclonal antibodies may be prepared by common hybridoma technology using RelA-associated inhibitor of the present invention or fragments thereof, as an immunogen. Polyclonal antibodies may also be prepared by common means which comprise inoculating host animals, (for example, a rat or a rabbit etc.), with RelA-associated inhibitor of the present invention and recovering immune serum.

[0039] The present invention also provides pharmaceutical compositions comprising a RelA-associated inhibitor of the present invention, or an antibody thereof, in association with a pharmaceutically acceptable diluent and/or carrier.

[0040] The present invention also provides a method for diagnosis of diseases etc. induced by NF κ B using an antibody against a RelA-associated inhibitor of the present invention. The various methods for diagnosis using such an antibody have been known. For example, it may be carried out by determination of amount of enzyme according to EIA method etc. using an antigen-antibody reaction.

[0041] The RelA-associated inhibitor of the present invention specified in (1) includes that which a part of their amino acid sequence is lacking (e.g., a polypeptide comprised of the only essential sequence for revealing a biological activity in amino acid sequence shown in SEQ ID NO. 1), that which a part of their amino acid sequence is replaced by other amino acids (e.g., those replaced by amino acid having a similar property) and that which other amino acids are added or inserted into a part of their amino acid sequence, as well as those comprising the amino acid sequence shown in SEQ ID NO. 1.

[0042] As known well, there are one to six kinds of codon as that encoding one amino acid (for example, one kind of codon for Methionine (Met), and six kinds of codon for Leucine (Leu) are known). Accordingly, the nucleotide sequence of cDNA can be changed in order to encode the polypeptide having the same amino acid sequence.

EP 1 146 054 A1

[0043] The cDNA of the present invention, specified in (2) includes a group of every nucleotide sequence encoding RelA-associated inhibitor in (1) shown in SEQ ID NO. 1. There is a probability that yield of a RelA-associated inhibitor is improved by changing a nucleotide sequence.

[0044] The cDNA specified in (3) is the embodiment of the cDNA shown in (2), and indicate the sequence of natural form.

[0045] The cDNA shown in (4) indicates the sequence of the cDNA specified in (3) with natural non-translational region.

[0046] (5) Sequences shown in SEQ ID NO. 4 reveal the correspondence between cDNA sequence in (4) shown in SEQ ID NO. 3 and amino acid sequence shown in (1).

[0047] cDNA carrying nucleotide sequence shown in SEQ ID NO. 3 and RelA-associated inhibitor comprising amino acid sequence shown in SEQ ID NO. 1 of the present invention may be prepared by the following method:

1) Identification of the protein capable for interacting on p65 may be carried out by yeast two-hybridization method.

The central part of p65 (possessing properties comprising a dimer domain, nucleus translocatin signal and multiple proline) is cloning into plasmid (pAS2-1 etc.) to contain yeast GAL4-binding domain in the same frame.

2) Human (placenta, brain etc.) cDNA library constructed in GAL4 transcription activating domain vector pACT2 is cloned using the obtained plasmid as a probe.

The yeast transformats are obtained by screening using yeast (Y190 strain etc.). From them, clones which are incubated on the culture for selection are screened according to blue-colouring by filter-lift-giactosidase assay.

3) Rescreening is carried out using alternative yeast (Y187 strain etc.) to confirm plasmid clone capable for interacting p65 probe specifically. It is possible to identify these clones according to both strands DNA sequencing.

4) The clones encoding RelA-associated inhibitor of the present invention may be obtained from the obtained clones by removing known ones.

5) Aimed full-length cDNA of about 6 kbp may be isolated by plaque-hybridization using the obtained DNA fragment from human library (placenta, brain etc.).

6) RelA-associated inhibitor of the present invention may be prepared from the isolated cDNA using expression cells (CHO cell, COS cell etc.) according to known methods.

[0048] Apart from the ankyrin repeats and SH3 domain, the RAI sequence is unrelated to that of any protein in current databases using BLAST research.

[0049] It is necessary to confirm whether the full-length or almost full-length cDNA has been obtained. It has been confirmed that the obtained cDNA is almost full-length by Northern blot analysis according to comparison with size of the obtained mRNA.

[0050] Once the nucleotide sequences shown in SEQ ID NOS. 2 and 3 are determined, cDNAs of the present invention are obtained by chemical synthesis, or by hybridization making use of nucleotide fragments which are chemically synthesized as a probe. Furthermore, cDNAs of the present invention may be obtained in desired amount by transforming a vector that contains the cDNA into a proper host, and culturing the transformant.

[0051] The polypeptides of the present invention may be prepared by:

(1) isolating and purifying from an organism or a cultured cell,

(2) chemically synthesizing, or

(3) using recombinant DNA technology etc.,

preferably, by the method described in (3) in an industrial production.

[0052] Examples of expression system (host-vector system) for producing a polypeptide by using recombinant DNA technology are the expression systems of bacteria, yeast, insect cells and mammalian cells.

[0053] In the expression of the polypeptide, for example, in E. Coli, the expression vector may be prepared by adding the initiation codon (ATG) to 5' end of a cDNA encoding mature peptide, connecting the cDNA thus obtained to the downstream of a proper promoter (e.g., trp promoter, lac promoter, λ PL promoter, T7 promoter etc.), and then inserting it into a vector (e.g., pBR322, pUC18, pUC19 etc.) which functions in an E. Coli strain.

[0054] Then, an E. Coli strain (e.g., E. Coli DH5 α strain, E. Coli JM109 strain, E. Coli HB101 strain, etc.) which is transformed with the expression vector described above may be cultured in an appropriate medium to obtain the desired polypeptide. When a signal peptide of bacteria (e.g., signal peptide of pel B) is utilized, the desired polypeptide may be also released in periplasm. Furthermore, a fusion protein with other polypeptide may be also produced readily.

[0055] In the expression of the polypeptide, for example, in a mammalian cells, for example, the expression vector may be prepared by inserting the cDNA encoding nucleotide sequence shown in SEQ ID NO. 3 into the downstream of a proper promoter (e.g., SV40 promoter, SR α promoter, LTR promoter, metallothionein promoter etc.) in a proper vector (e.g., retrovirus vector, papilloma virus vector, vaccinia virus vector, SV40 vector, etc.). A proper mammalian

cell (e.g., human undifferentiated eosinophilic leukemia EOL cell, COS-7 cell, CHO cell, mouse L cell etc.) is transformed with the expression vector thus obtained, and then the transformant is cultured in a proper medium to express the aimed polypeptides. Thus obtained polypeptides may be isolated and purified with the known biochemical methods.

5 Industrial Utility

[0056] RelA-associated inhibitor (polypeptides) of the present invention is capable of binding to p65 in nucleus, which is a subunit of transcription factor NF κ B, and inhibiting activity of NF κ B and transcription of gene in nucleus. Therefore, it is useful for treatment and/or prevention of adult respiratory distress syndrome (ARDS), asthma, Allograft rejection, inflammatory diseases (inflammatory arthritis, angitis etc.), ischemic diseases, autoimmune diseases (especially, AIDS), metastasis and invasion of cancer, vasoconstriction and diseases induced by NF κ B besides the above. Further, it also relates to cardiogenesis and suppression of cardiac inflammation, so it may be used for regenerating cardiomyocyte cells.

[0057] In addition, the antibody of the present invention may be used for diagnosis of the above diseases.

[0058] A pharmaceutical composition comprising RelA-associated inhibitor, antibody against it or antisense thereof of the present invention and pharmaceutically acceptable diluent and/or a carrier is also included in the present invention.

[0059] RelA-associated inhibitor, cDNA encoding it, antibody against it and antisense of the present invention may be administered as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parental administration.

[0060] Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules. Capsules include soft or hard capsules.

[0061] The doses to be administered depend upon age, body weight, symptom, desired therapeutic effect, route of administration, and duration of the treatment etc. in human adults, one dose per person is generally between 100 μ g and 100 mg, by oral administration, up to several times per day, and between 10 μ g and 100 mg, by parental administration up to several times per day.

[0062] As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

[0063] The antibody against RelA-associated inhibitor of the present invention may be used for diagnosis of the above diseases.

[0064] An quantitative assay of RelA-associated inhibitor of the present invention in the body may be carried out using polyclonal or monoclonal antibody against it. Based on the assay, it is possible to study the relationship between RelA-associated inhibitor of the present invention and diseases or diagnose such diseases.

[0065] Polyclonal and monoclonal antibodies can be prepared using the polypeptide of the present invention or its fragment as an antigen by conventional methods. Further, purification or gene cloning of proteins (NF κ B) capable of binding to the RelA-associated inhibitor (polypeptide) can be performed using the present polypeptide. In addition, the present polypeptide may be used for screening RelA-associated inhibitor agonist or antagonist.

[0066] cDNAs of the invention are useful as not only the important and essential template for the production of the RelA-associated inhibitor of the invention which is expected to be largely useful, but also be useful for diagnosis or therapy (for example, treatment of gene lacking, treatment to stop the expression of the RelA-associated inhibitor by antisense DNA (RNA)). Genomic DNA may be isolated using the cDNA of the invention, as a probe. As the same manner, a human gene encoding which can be highly homologous to the cDNA of the invention, that is, which encodes a polypeptide highly homologous to the RelA-associated inhibitor of the invention and a gene of animals excluding human which can be highly homologous to the cDNA of the invention, also may be isolated.

45

Best Mode carrying out the Invention

[0067] The invention is illustrated by the following Examples and Reference Examples, but not limit the invention.

50 Example 1: Construction of plasmids-plasmids

[0068] Construction of plasmids-plasmids were constructed by standard methods.

[0069] The human p65 (amino acids 176-405) fragment was cloned into pAS2-1 (Clontech Co., Palo Alto) by the yeast two-hybrid system.

[0070] PCR amplification using 5' and 3' oligonucleotides containing BamHI restriction sites, i.e., Forward: 5'-GGCGGATCCCTCCGCCTGCCGCTGTC- 3' (SEQ ID NO. 5), and Reverse: 5'-GCTGGATCCGGGGCAGGGGCTGGAGCC-3' (SEQ ID NO. 6) was carried out. The resulting plasmid was named pAS2-1-p65 (176-405). pACT2-p35, encoding the largest RelA Associated Inhibitor (hereinafter abbreviated as RAI) insert obtained from library screening,

EP 1 146 054 A1

was cut with EcoRI and XhoI. This EcoRI-XhoI fragment was purified and cloned into EcoRI-XhoI-digested vector pGEX-5X-2 (Pharmacia Co.).

[0071] RAI cDNA was cloned as described below.

[0072] The full length RAI was amplified using the oligonucleotides containing Sall and BamHI restriction sites, i.e., Forward: 5'-CAATGGTCGACATGGATCTGACTCTTGCTG-3' (SEQ ID NO. 7) and Reverse: 5'-GATCAGGATCCT-CAGGCCAAGCTCCTTTGT-3' (SEQ ID NO. 8) respectively, and cloned as a Sall-BamHI fragment into plasmid pEGFP-C1 to obtain plasmid pEGFP-RAI which may produce fusion protein with RAI in frame with GFP.

[0073] pEGFP-RAI (1-146) was prepared from pEGFP-RAI by cutting with BssHII and BamHI, blunt ended with Klenow enzyme and cloning into pEGFP-C1.

[0074] The pEGFP-RAI (132-351) was prepared by amplifying the corresponding RAI fragment by PCR using the oligonucleotides F132 containing EcoRI and BamHI sites, i.e., Forward: 5'-GCTTCGAAT TCTGTGCTGCGGAAGGCG-3' (SEQ ID NO. 9) and Reverse: 5'-GATCAGGATCCTCAGGCCAAGCTCCTTTGT-3' (SEQ ID NO. 10) respectively, and by cloning into pEGFP-C1. pFLAG-CMV-RAI was prepared by inserting the full-length RAI fragment from pEGFP-RAI into Sall and BamHI restriction sites of pFLAG-CMV-2 vector.

[0075] All the PCR were carried out using Expand high fidelity system (Boehringer Mannheim Co.).

[0076] All the constructs were confirmed by dideoxynucleotide sequencing using ABI PRISM dye terminator cycle sequencing ready reaction kit (Perkin Elmer Co.).

[0077] Plasmids PG13-Luc containing a generic p53 response element, and pCMV-p53wt expressing wild type human p53, were generous gifts from Dr. B. Vogelstein. The constructions of 4kBw-Luc and 4kBm-Luc have been carried out by known methods described in articles.

[0078] Yeast two-hybrid screen - pAS2-1-p65 (176-405) was used as probe to screen human placenta and brain cDNA libraries according to the Matchmaker Two-Hybrid System protocol (Clontech Co.). Positive yeast clones were selected by prototrophy for histidine and by expression of β -galactosidase. Library derived from plasmids were rescued from positive clones and transformed into E. coli HB101.

[0079] Subsequent two-hybrid assays were carried out by introducing the plasmids into yeast strain Y187 carrying a Gal1-regulated reporter gene and detected the expression of β -galactosidase to confirm the specific binding.

[0080] Plasmids containing cDNA clones that specifically interact with p65 (176-405) were identified by restriction mapping, PCR using gene specific primers, and DNA sequencing of both strands.

[0081] Sequence Network BLAST searches were conducted by using the National Center for Biotechnology Information (NCBI) on-line service.

Example 2: Culturing cell and transfection

[0082] HeLa, 293T and Saos-2 and COS-1 cells were incubated at 37°C in Dulbecco's modified Eagle's medium with 10% heat-inactivated fetal bovine serum (FBS), 1 mM glutamate, 100 U/ml penicillin, and 100 mg/ml streptomycin. Jurkat human T cells were maintained in RPMI 1640 with 10% FBS plus antibiotics.

[0083] Cells were transfected using SuperFect transfection reagent (Qiagen Co.) according to the manufacturer's recommendations.

Example 3: Purification and expression of recombinant proteins

[0084] pGEX-5X-2 plasmid encoding glutathione S-transferase (GST)-fusion proteins were transformed in E. coli strain BL21 (DE3) pLysS following induction with isopropyl-1-thio- β -D-galactopyranoside (IPTG, 0.1 mM) at 28°C overnight. Recombinant GST-fusion proteins were purified by incubating the bacterial extracts in buffer A (Tris-HCl (pH 7.4; 50 mM), DTT (1 mM), EDTA (1 mM), EGTA (0.1 mM), NaCl (100 mM), benzamidine (1 mM), phenylmethylsulfonyl fluoride (PMSF) (0.1 mM), tosylphenylalanylchloromethylketone (0.1 mM), 0.25% (v/v) Nonidet P-40 (NP-40)) with glutathione-sepharose beads (Pharmacia Biotech Co.).

[0085] The beads were washed five times with ice-cold buffer A and suspended in buffer A (1 ml). The purification and examination of quantity of bound GST fusion proteins were carried out by SDS-PAGE using 5-20% sodium dodecyl sulfate-polyacrylamide and by stain using Coomassie brilliant blue.

Example 4: In vitro assays

[0086] ³⁵S-methionine-labeled p65 was synthesized by using the TNT T7/SP6 wheat germ extract coupling system (Promega Co.) according to the manufacturer's protocols.

[0087] For in vitro protein-protein interaction studies, an equal amount of the in vitro-translated ³⁵S-methionine-labeled p65 was incubated with 5 mg of purified GST-RAI fusion proteins or GST alone (as a negative control) that were bound to glutathione-sepharose beads at 25 °C for 1 h in buffer A (250 ml).

EP 1 146 054 A1

[0088] The beads were washed by resuspension and centrifugation five times with 1 ml of ice-cold binding buffer A containing 0.1% NP-40. Bound proteins were eluted with an equal volume of SDS loading buffer, boiled for 3 min, dissolved into 5-20% SDS-PAGE, and visualized by autoradiography.

5 Example 5: isolation of full-length RAI

[0089] A fragment encoding the longest RAI obtained from yeast two-hybrid screen was used as a hybridization probe to screen a human placenta 5'-STRETCH PLUS cDNA library (Clontech Co.). The probe was labeled by ³²P using Prime-It Random Primer Labeling Kit (Stratagene). Hybridization was performed according to the manufacturer's
10 recommendations. The filters were washed to a final stringency of 0.1 x SSC-0.5% SDS at 65°C and exposed to X-ray film (X-Omat AR; Eastman Kodak Co.) overnight with intensifying screens. The films were developed and plaques hybridizing on filters were identified and isolated. Phages were eluted from agarose plugs in SM buffer and stored at 4°C (primary plaque pools). Secondary and tertiary plaque purifications were performed in similar fashion to that for the primary pools and a series of such procedures was repeated until single plaques could be isolated.

15

Example 6: Western blotting

[0090] Full-length RAI was cloned into a CMV promoter expression vector designed to place a FLAG epitope tag at the 5' end of the open reading frame. 293T cells were transfected using SuperFect transfection reagent as described
20 above. Proteins were isolated from extraction of whole cells in a SDS-containing buffer. Western blotting was performed by a standard technique, using anti-FLAG antibody (Santa Cruz Co.) at a dilution of 1/1,000. Secondary antibody, horseradish peroxidase-conjugated anti-rabbit IgG antibody was used at a dilution of 1/2,500, and protein bands were visualized by enhanced chemiluminescence (Amersham Co.).

25 Example 7: Co-immunoprecipitation

[0091] After transfection, 293T cells were cultured for 24 hour and then harvested (proliferated). After washing with PBS, cells were lysed in 350 ml ice-cold lysis buffer (Tris HCl (pH 7.4; 50 mM), 150 mM NaCl, 2 mM EDTA, 1 mM PMSF, 1 mM DTT, 0.2% NP-40, 10 mM NaF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 µg/ml pepstatin A) for 30
30 min. The lysate was cleared by centrifugation. The supernatants were incubated with anti-FLAG M2 murine monoclonal antibody (Kodak Co.) or control mouse monoclonal antibody (Dako Co.) or rabbit polyclonal I κB-α antibody (Santa Cruz Co.) overnight at 4 °C and then with protein A-Sepharose (Pharmacia Co.) for 4 h. The beads were washed six times with 1 ml lysis buffer. Bound proteins were eluted with an equal volume of SDS loading buffer and resolved on 10% SDS-PAGE. Western blot was conducted as described above using anti-NF-κB p65 (C-20) antibody (Santa Cruz
35 Co.).

Example 8: Northern blot hybridization

[0092] Northern blot hybridization of the human multiple tissue blots (Clontech Co.) was performed according to the
40 manufacturer's recommendations. A full-length of RAI cDNA was used as a probe. The blots were also probed with an β-actin fragment to confirm that equal amount of RNAs was blotted.

Example 9: Microscopic examination

[0093] HeLa cells were cultured in 4-well chamber slides and transfected with plasmids expressing various GFP fusion proteins using SuperFect transfection reagent (Qiagen Co.). After 24 h, cells were fixed by reacting in 4% paraformaldehyde for 15 min and stained with the DNA-binding dye Hoechst-33342 at room temperature for 15 min followed
45 by washing in phosphate-buffered saline (PBS). The intracellular locations were examined by fluorescence microscopy.

50 Example 10: Immunofluorescence microscopy

[0094] pEGFP-RAI (0.1 mg) was transfected into HeLa cells cultured in 4-well chamber slides. Twenty-four hour after transfection, cells were untreated or treated with 10 ng/ml TNF-α, then were immuno-stained according to the methods described as hereinbefore. Briefly, cells were fixed with 4% (w/v) paraformaldehyde/PBS for 10 min at room temperature
55 and then were permeabilized by 0.5% Triton X-100/PBS for 20 min at room temperature. They were then incubated with rabbit polyclonal antibody against p65 (Santa Cruz Co.) for 1 h at 37 °C. After washing with PBS, the cells were incubated with TRITC-conjugated goat anti-rabbit IgG antibody (Cappel Organon Teknika Co.) for 30 min at 37°C. Then the cells were stained with Hoechst-33342 at room temperature for 15 min to view the nuclear morphology. The

slides were examined by fluorescence microscopy.

Example 11: Luciferase Assay

- 5 **[0095]** HeLa and Saos-2 cells were cultured in 12-well plates and transfections were performed with SuperFect transfection reagent (Qiagen Co.). For each transfection, 50 ng of κ B-dependent or mutant reporter plasmid (4kBw-Luc or 5kBm-Luc) or 250 ng of p53-dependent luciferase reporter plasmid (PG13-Luc) and 30 ng of internal control plasmid pRL-TK were used. The empty vector pEBVHisB or pFLAG-CMV-2 was used to adjust the total amount of DNA transfected to 1.5 μ g. Twenty-four hours post-transfection, cells were harvested to measure the luciferase activity (Sato, T. et al, AIDS Res. Hum. retrovir. 14, 293-298 (1998)). Jurkat cells were transfected with indicated plasmids. Twenty-four hour post-transfection, the cells were induced by 5 ng/ml TNF- α for 24 h and harvested for luciferase assay.

Example 12: Gel Electrophoretic Mobility Shift Assay

- 15 **[0096]** 293T cells were transfected for 24 h and nuclear extracts were prepared according to the known methods described previously (Okamoto, T. et al, Virology 177, 606-614 (1990)). The nuclear pellet was lysed in 35 ml of extraction buffer (50 mM HEPES, pH7.4, 50 mM KCl, 350 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, 10% glycerol).
- 20 **[0097]** The protein content was measured by the DC protein Assay (Bio-RAD Co.). The gel electrophoretic mobility shift assay (EMSA) was performed according to the known methods described previously (Yang, J.-P., et al, FEBS Lett. 361, 89-96 (1995); Liu, Z.-Q., et al, FEBS Lett. 385, 109-113 (1996)) using the kB sequence taken from the human immunodeficiency virus LTR. As a control, Oct-consensus oligonucleotide: 5'-TGTCGAATGCAAATCACTAGAA-3' (SEQ ID NO. 11) was used. Oligonucleotides were labeled using DNA polymerase Klenow fragment (Takeda Biomedicals Co.) and [α -³²P]dATP (3000 Ci/mmol, ICN Pharmaceuticals Inc.).
- 25 **[0098]** DNA binding reactions were performed at room temperature for 15 min in 10- μ l reaction voluminous containing 5 μ g of nuclear extracts. Analysis of binding complexes was performed by electrophoresis in 5% native polyacrylamide gels with 0.5x tris-borate-EDTA buffer, followed by autoradiography. For DNA competition experiments, unlabeled competitor oligonucleotides were added into the reaction mixture at 50-fold molar excess over the probe.

30 Results: Isolation of RAI cDNA clones as a p65-binding protein

- [0099]** The yeast two-hybrid system has been employed to identify proteins that interact with p65. DNA fragment encoding amino acids (176-405) of p65, which contained the dimerization domain, nuclear localization signal and the proline-rich motif, was cloned into pAS2-1 containing a DNA-binding domain of yeast GAL4 in frame. The resulting plasmid, pAS2-1-p65 (176-405), was used as a probe to screen human cDNA libraries (placenta and brain) that had been constructed in GAL4 transcriptional activation domain vector pACT2. The yeast strain Y190 was used for screening. From approximately 1.56×10^6 Y190 yeast transformants, 78 colonies grew on selective medium and turned blue when tested in a filter lift galactosidase assay.
- 35 **[0100]** Resulting from re-screening using Yeast strain Y187, 63 of plasmid clones encoding the proteins which specifically interacted with the p65 bait were found. These clones were then characterized by DNA sequence analysis of both strands.
- 40 **[0101]** Primary nucleotide sequencing revealed that in addition to those already identified as p65-binding proteins, such as genes encoding I κ B- β /Trip9 (4 clones), p50/p105 (3 clones), p65/RelA (2 clones), c-Rel (1 clone) and 53BP2 (2 clones), four clones of an unidentified gene encoding a protein not previously described in the GenBank database were isolated (all of them were derived from human placenta cDNA library).
- 45 **[0102]** The present inventor has called this new protein RelA Associated Inhibitor (RAI). These four clones identified by the two-hybrid screen shared the same 3' end, but contained different insert sizes.
- [0103]** To confirm the direct interaction between p65 and RAI, in vitro binding assay between recombinant RAI and p65 proteins was performed. The cDNA insert from plasmid pACT2-RAI was cloned in frame into the GST expression plasmid for production of the GST-RAI fusion protein.
- 50 **[0104]** The GST fusion proteins were expressed in E. coli and purified by glutathione-sepharose beads (Fig. 1, lanes 1 and 2).
- [0105]** [³⁵S]methionine-labeled p65 was synthesized by in vitro transcription and translation protocol using wheat germ extract (Fig. 1, lane 3).
- 55 **[0106]** The purified GST-fusion proteins bound to glutathione-sepharose beads were incubated with the in vitro synthesized p65 protein. The beads were washed and bound material was analyzed by SDS-PAGE followed by autoradiography. As shown in Fig. 1, p65 interacted strongly with RAI (lane 5). Binding between p65 and RAI was considered as specific because no interaction of p65 was observed with the control GST protein (lane 4).

Example 13: Isolation of full-length RAI

[0107] The four independent clones isolated from the yeast two-hybrid screen were partial-length cDNA derived from the same gene. Plaque hybridization of a human placenta cDNA library with the partial cDNA fragment of RAI isolated from the two-hybrid screen was performed to obtain a full-length clone. About 10^6 plaques were screened. Nine cDNA clones were isolated with approximately 1 kb to 6 kb in length. Two longest cDNAs were sequenced on both strands and were found to contain the complete open reading frame (ORF) for RAI. The clones differed at their 5' end, and each contained all of the sequences present in pACT2-RAI. Both contained Alu repeat element in their 5' untranslated regions. The likely translation initiation codon of RAI was preceded by an in-frame stop codon located 27 bp upstream. Although the nucleotide sequence 5' of the first ATG (CTGGCGATG) does not resemble the consensus initiation sequence, the present inventor designated this ATG as the putative translation start site. DNA sequence analysis revealed an open reading frame predicted to encode a putative protein of 351 amino acid residues with a predicted molecular mass of 40 kDa. Interestingly, a BLAST search revealed that the C-terminal of this protein has extensive homology to the C-terminal region of 53BP2, previously reported as p53 binding protein in a yeast two hybrid screen (Iwabuchi, K. et al, Proc. Natl. Acad. Sci. USA 91, 6098-6102 (1994)).

[0108] RAI protein was predicted to contain four consecutive ankyrin repeats (145 Arg-174 Asn, 176 Pro-207 Ala, 209 Val-241 Ala, 243 Phe-275 Glu) and an SH3 domain (287 Tyr-388 Phe) at its C-terminus as that of 53BP2, with 52% amino acid identity with 53BP2 at the C-terminal of 223 amino acid residues.

[0109] Apart from the ankyrin repeats and SH3 domain, the RAI sequence is unrelated to that of any protein in current databases using BLAST research.

Example 14: Tissue distribution of RAI in human tissues

[0110] To determine the expression pattern of RAI, present inventor performed a Northern blot analysis on a human multi-tissue blot. As shown in Fig. 2, the RAI mRNA was detected as an approximately 3.4-kb and 6.0-kb band in most cases. From Fig. 2 clearly, the expression of RAI mRNA was significantly high in human heart, placenta and prostate while it was markedly reduced in liver, skeletal muscle, testis and peripheral blood leukocyte.

Example 15: Inhibitory action of RAI on NF κ B-dependent transactivation

[0111] Since RAI was shown to bind p65 through its ankyrin repeats and SH3 domain as similarly to I κ B family proteins, the present inventor confirmed whether RAI had any effect on the κ B-dependent transcriptional activation. The luciferase reporter plasmid containing four tandem copies of the κ B sequence was co-transfected into 293 T cells with an expression vector for FLAG-RAI and/or p65 expression vector. Twenty-four hours after transfection, luciferase activities were determined. As shown in Fig. 3, co-transfected p65-expressing plasmid as an activator strongly trans-activated the reporter gene (Fig. 3, lane 9). Co-transfection with the RAI expressing plasmid resulted in the inhibition of the p65-induced NF κ B activity in a dose-dependent manner. Although to a lesser extent, the inhibitory effect of RAI on the basal level of κ B-dependent luciferase expression was observed (Fig. 3, lanes 11, 13 and 15).

EP 1 146 054 A1

Sequence Listing

5 <110> ONO Pharmaceutical Co., Ltd.

10 <120> Rel A associated Inhibitor, Preparation and Use thereof

 <130> 11633/CH

15 <140> EP 99 973 038.5

 <141> 1999-12-02

20 <150> PCT/JP99/06753

 <151> 1999-12-02

25 <150> JP 10-344038

 <151> 1998-12-3

30 <160> 11

35 <170> PatentIn Ver. 2.0

 <210> 1

40 <211> 351

 <212> PRT

 <213> Homo sapiens

45 <220>

 <221> DOMAIN

50 <222> (145)...(174)

 <223> Ankyrin repeat

55

EP 1 146 054 A1

<220>
 <221> DOMAIN
 5 <222> (176)...(207)
 <223> Ankyrin repeat

 10 <220>
 <221> DOMAIN
 <222> (209)...(241)
 15 <223> Ankyrin repeat

 <220>
 20 <221> DOMAIN
 <222> (243)...(275)
 <223> Ankyrin repeat

 25 <220>
 <221> DOMAIN
 30 <222> (287)...(338)
 <223> SH3 domain

 35 <400> 1
 Met Trp Met Lys Asp Pro Val Ala Arg Pro Leu Ser Pro Thr Arg Leu
 1 5 10 15
 40 Gln Pro Ala Leu Pro Pro Glu Ala Gln Ser Val Pro Glu Leu Glu Glu
 20 25 30
 Val Ala Arg Val Leu Ala Glu Ile Pro Arg Pro Leu Lys Arg Arg Gly
 45 35 40 45
 Ser Met Glu Gln Ala Pro Ala Val Ala Leu Pro Pro Thr His Lys Lys
 50 55 60
 50 Gln Tyr Gln Gln Ile Ile Ser Arg Leu Phe His Arg His Gly Gly Pro
 65 70 75 80
 Gly Pro Gly Gly Arg Ser Gln Ser Cys Pro Pro Ser Leu Arg Asp Leu
 55 85 90 95

EP 1 146 054 A1

Arg Pro Gly Gln Gly Pro Leu Leu Leu Pro His Gln Leu Pro Phe His
100 105 110
5 Arg Pro Ala Pro Ser Gln Ser Ser Pro Pro Glu Gln Pro Gln Ser Met
115 120 125
10 Glu Met Arg Ser Val Leu Arg Lys Ala Gly Ser Pro Arg Lys Ala Arg
130 135 140
Arg Ala Arg Leu Asn Pro Leu Val Leu Leu Leu Asp Ala Ala Leu Thr
145 150 155 160
15 Gly Glu Leu Glu Val Val Gln Gln Ala Val Lys Glu Met Asn Asp Pro
165 170 175
Ser Gln Pro Asn Glu Glu Gly Ile Thr Ala Leu His Asn Ala Ile Cys
20 180 185 190
Gly Ala Asn Tyr Ser Ile Val Asp Phe Leu Ile Thr Ala Gly Ala Asn
195 200 205
25 Val Asn Ser Pro Asp Ser His Gly Trp Thr Pro Leu His Cys Ala Ala
210 215 220
Ser Cys Asn Asp Thr Val Ile Cys Met Ala Leu Val Gln His Gly Ala
30 225 230 235 240
Ala Ile Phe Ala Thr Thr Leu Ser Asp Gly Ala Thr Ala Phe Glu Lys
35 245 250 255
Cys Asp Pro Tyr Arg Glu Gly Tyr Ala Asp Cys Ala Thr Tyr Leu Ala
260 265 270
40 Asp Val Glu Gln Ser Met Gly Leu Met Asn Ser Gly Ala Val Tyr Ala
275 280 285
Leu Trp Asp Tyr Ser Ala Glu Phe Gly Asp Glu Leu Ser Phe Arg Glu
45 290 295 300
Gly Glu Ser Val Thr Val Leu Arg Arg Asp Gly Pro Glu Glu Thr Asp
305 310 315 320
50 Trp Trp Trp Ala Ala Leu His Gly Gln Glu Gly Tyr Val Pro Arg Asn
325 330 335
Tyr Phe Gly Leu Phe Pro Arg Val Lys Pro Gln Arg Ser Lys Val
55 340 345 350

EP 1 146 054 A1

<210> 2
 <211> 1053
 <212> DNA
 <213> Homo sapiens

<400> 2
 atgtggatga aggaccctgt agcaaggcct ctcagcccca cgaggctgca gccagcactg 60
 ccaccggagg cacagtcggt gcccgagctg gaggaggtgg cacgggtggt ggcggaatt 120
 ccccggcccc tcaaacgcag gggctccatg gagcaggccc ctgctgtggc cctgccccct 180
 acccacaaga aacagtacca gcagatcatc agccgcctct tccatcgtca tggggggcca 240
 gggcccgggg ggcggagcca gagctgtccc ccatcactga gggatctgag gccagggcag 300
 ggccccctgc tcctgcccc aagctccca ttccaccgcc cggccccgtc ccagagcagc 360
 ccaccagagc agccgcagag catggagatg cgctctgtgc tgcggaaggc gggctccccg 420
 cgcaaggccc gccgcgcgcg cctcaaccct ctggtgctcc tcctggacgc ggcgctgacc 480
 ggggagctgg aggtggtgca gcaggcgggtg aaggagatga acgacccgag ccagcccaac 540
 gaggagggca tcaactgcctt gcacaacgcc atctgcggcg ccaactactc tatcgtggat 600
 ttctcatca ccgcgggtgc caatgtcaac tcccccgaca gccacggctg gacacccttg 660
 cactgcgcgg cgctgtgcaa cgacacagtc atctgcatgg cgctggtgca gcacggcgct 720
 gcaatcttcg ccaccacgct cagcgacggc gccaccgcct tcgagaagtg cgacccttac 780
 cgcgagggtt atgctgactg cgccacctac ctggcagacg tcgagcagag tatgggctg 840
 atgaacagcg gggcagtgtg cgctctcttg gactacagcg ccgagttcgg ggacgagctg 900
 tccttcgcgc agggcgagtc ggtcaccgtg ctgcggaggg acgggccgga ggagaccgac 960
 tgggtggtgg ccgcgctgca cggccaggag ggctacgtgc cgcggaacta cttcgggctg 1020
 ttccccaggg tgaagcctca aaggagtaaa gtc 1053

<210> 3
 <211> 2640
 <212> DNA
 <213> Homo sapiens

<400> 3
 ggaattcgcg gccgcgtcga caaacaagtg agtctcggtt ggagtgcagt ggtgcagtgg 60
 tgcaatctcg gctcactgca acctccgctt cctgggttca agcgattcct gtgcctcggc 120

EP 1 146 054 A1

cttccgagta gctgggattg caggcgtgtg ccaccacgcc cggctaattt tttttttttt 180
 tttttttttt ttgtattttt agtagagaca gggttcttac catgttggc aggctggtct 240
 5 caaactcctg atctcaagag atgtggcctg cctccggcct cccaaagtgc tgggattaca 300
 ggggtgttgag ccactctgac tcagccaata atgcatattt ttatttccac ctgctttact 360
 gtcagaatga gtaagacaga gaagaaatca ttaaaccacca ggattctact tgcctgctgg 420
 10 agttttctgc ctgagatggt aggagaggaa actctcagga tctcagaaaa tcacatctat 480
 cacggttggg agaagtagat tctagagtca gccagaatga gttcaagtcc caactgcatg 540
 gctttgggca actgactgtc ctctctgagg ccagattcc ctttcggtaa tgtggagatg 600
 15 gcagtgtatc tacctcacia agcagtgtg agattacaat aaggtaggca tgtaaagcgc 660
 caggcacata ctaactgtc aataaatggg aggcatcata attgtatatt attcacagcc 720
 caaggaaagt gtagcccaga gagggcaagg aacttgaccc tgagggtcaac acagaaaatc 780
 20 atgtgctggt tgtatgccct ggaagttgtg gagagggagt gttgggtgtc ttcctgggga 840
 cctgtcctct gatgggetct tgttccggct aggaccccc aaacccccca ccgagctgga 900
 gcctgagccg gagatagagg ggctgctgac accagtgtg gaggctggcg atgtggatga 960
 25 aggaccctgt agcaaggcct ctacgcccc cgaggctgca gccagcactg ccaccggagg 1020
 cacagtcggt gcccagctg gagggagtgg cacgggtgtt ggcggaatt ccccgcccc 1080
 tcaaacgcag gggctccatg gagcaggccc ctgtgtggc cctgccccct acccacaaga 1140
 30 aacagtacca gcagatcatc agccgcctct tccatcgtca tggggggcca gggccgggg 1200
 ggcggagcca gagctgtccc ccactactga gggatctgag gccagggcag gggccctgc 1260
 tcdtgcacca ccagctcca ttccaccgcc cggccccgtc ccagagcagc ccaccagagc 1320
 35 agccgcagag catggagatg cgctctgtg tgcggaaggc gggctcccc cgcaaggccc 1380
 gccgcgcgc cctcaaccct ctggtgtccc tctggacgc ggcgtgacc ggggagctgg 1440
 aggtggtgca gcaggcgtg aaggagatga acgaccgag ccagcccaac gaggagggca 1500
 40 tcaactgcctt gcacaacgcc atctgcggcg ccaactactc tatcgtggat ttcctcatca 1560
 ccgcgggtgc caatgtcaac tccccgaca gccacggctg gacacccttg cactgcgcgg 1620
 cgtcgtgcaa cgacacagtc atctgcatgg cgctggtgca gcacggcgct gcaatcttcg 1680
 45 ccaccacgct cagcgacggc gccaccgct tcgagaagtg cgacccttac cgcgagggtt 1740
 atgctgactg cgccacctac ctggcagacg tcgagcagag tatggggctg atgaacagcg 1800
 gggcagtgtc cgctctctgg gactacagcg ccgagttcgg ggacgagctg tccttccgcg 1860
 50 agggcgagtc ggtcaccgtg ctgcggaggg acgggccgga ggagaccgac tgggtggtggg 1920
 ccgcgtgca cggccaggag ggctacgtgc cgcggaacta cttcgggctg tccccaggg 1980
 tgaagcctca aaggagtaaa gtctagcagg atagaaggag gtttctgagg ctgacagaaa 2040
 55 caagcattcc tgccttcctt ccagacctct ccctctgttt tttgctgctt ttatctgcac 2100

EP 1 146 054 A1

ccctcaccct gctggtggtg gtccttgcca ccggttctct gttctcctgg aagtccaggg 2160
aagaaggagg gcccagcct taaatttagt aatctgcctt agccttgga ggtctgggaa 2220
5 gggctggaaa tcaactggga caggaaacca cttccttttg ccaaatacaga tcccgtecaa 2280
agtgcctccc atgcctacca ccatcatcac atccccagc aagccagcca cctgcccagc 2340
cgggcctggg atgggccacc acaccactgg atattcctgg gagtcaactgc tgacaccatc 2400
10 tctcccagca gtcttggggt ctgggtggga aacattggtc tctaccagga tccctgcccc 2460
acctctcccc aattaagtgc cttcacacag cactggttta atgtttataa acaaaataga 2520
gaaactttcc ttataaataa aagtagtttg cacagaaaaa aaaaaaacac aaccttcggc 2580
15 cgccccacca agctctgtct ccaaaaaaaaa aaaaaaaaaa aaaaaaactc gagagttcta 2640

<210> 4

20 <211> 2640

<212> DNA

<213> Homo sapiens

25

<220>

<221> CDS

30

<222> (951)...(2003)

<400> 4

35 ggaattcgcg gccgcgtcga caaacaagtg agtctcggtt ggagtgcagt ggtgcagtgg 60
tgcaatctcg gctcaactgca acctccgcct cctgggttca agcgattcct gtgcctcggc 120
cttccgagta gctgggattg caggcgtgtg ccaccacgcc cggctaattt tttttttttt 180
40 tttttttttt ttgtattttt agtagagaca gggttcttac catgttgagg aggctggtct 240
caaactcctg atctcaagag atgtggcctg cctccggcct cccaaagtgc tgggattaca 300
gggtgttgag ccactctgac tcagccaata atgcatattt ttatttccac ctgctttact 360
45 gtcagaatga gtaagacaga gaagaaatca ttaaaccacca ggattctact tgctgtctgg 420
agttttctgc ctgagatgtt aggagaggaa actctcagga tctcagaaaa tcacatctat 480
cacggttggt agaagtagat tctagagtca gccagaatga gttcaagtcc caactgcatg 540
50 gctttgggca actgactgtc ctctctgagg ccagattcc ctttcggtaa tgtggagatg 600
gcagtgtatc tacctcaca agcagtggtg agattacaat aaggtaggca tgtaaagcgc 660
caggcacata ctaactgtc aataaatggg aggcataata attgtatatt attcacagcc 720
55 caaggaaagt gtagcccaga gagggcaagg aacttgaccc tgaggtaaac acagaaaatc 780

EP 1 146 054 A1

atgtgctggt tgtatgccct ggaagttgtg gagagggagt gttgggtgtc ttcctgggga 840
cctgtcctct gatgggctct tgttccggct aggaccccc aaacccccca ccgagctgga 900
5 gcctgagccg gagatagagg ggctgctgac accagtgtg gaggctggcg atg tgg 956
Met Trp
1
10 atg aag gac cct gta gca agg cct ctc agc ccc acg agg ctg cag cca 1004
Met Lys Asp Pro Val Ala Arg Pro Leu Ser Pro Thr Arg Leu Gln Pro
5 10 15
15 gca ctg cca ccg gag gca cag tcg gtg ccc gag ctg gag gag gtg gca 1052
Ala Leu Pro Pro Glu Ala Gln Ser Val Pro Glu Leu Glu Glu Val Ala
20 25 30
20 cgg gtg ttg gcg gaa att ccc cgg ccc ctc aaa cgc agg ggc tcc atg 1100
Arg Val Leu Ala Glu Ile Pro Arg Pro Leu Lys Arg Arg Gly Ser Met
35 40 45 50
25 gag cag gcc cct gct gtg gcc ctg ccc cct acc cac aag aaa cag tac 1148
Glu Gln Ala Pro Ala Val Ala Leu Pro Pro Thr His Lys Lys Gln Tyr
55 60 65
30 cag cag atc atc agc cgc ctc ttc cat cgt cat ggg ggg cca ggg ccc 1196
Gln Gln Ile Ile Ser Arg Leu Phe His Arg His Gly Gly Pro Gly Pro
70 75 80
35 ggg ggg cgg agc cag agc tgt ccc cca tca ctg agg gat ctg agg cca 1244
Gly Gly Arg Ser Gln Ser Cys Pro Pro Ser Leu Arg Asp Leu Arg Pro
85 90 95
40 ggg cag ggc ccc ctg ctc ctg ccc cac cag ctc cca ttc cac cgc ccg 1292
Gly Gln Gly Pro Leu Leu Leu Pro His Gln Leu Pro Phe His Arg Pro
100 105 110
45 gcc ccg tcc cag agc agc cca cca gag cag ccg cag agc atg gag atg 1340
Ala Pro Ser Gln Ser Ser Pro Pro Glu Gln Pro Gln Ser Met Glu Met
115 120 125 130
50 cgc tct gtg ctg cgg aag gcg ggc tcc ccg cgc aag gcc cgc cgc gcg 1388
Arg Ser Val Leu Arg Lys Ala Gly Ser Pro Arg Lys Ala Arg Arg Ala
135 140 145
55 cgc ctc aac cct ctg gtg ctc ctc ctg gac gcg gcg ctg acc ggg gag 1436

EP 1 146 054 A1

	Arg Leu Asn Pro Leu Val Leu Leu Leu Asp Ala Ala Leu Thr Gly Glu	
	150 155 160	
5	ctg gag gtg gtg cag cag gcg gtg aag gag atg aac gac ccg agc cag	1484
	Leu Glu Val Val Gln Gln Ala Val Lys Glu Met Asn Asp Pro Ser Gln	
	165 170 175	
10	ccc aac gag gag ggc atc act gcc ttg cac aac gcc atc tgc ggc gcc	1532
	Pro Asn Glu Glu Gly Ile Thr Ala Leu His Asn Ala Ile Cys Gly Ala	
	180 185 190	
15	aac tac tct atc gtg gat ttc ctc atc acc gcg ggt gcc aat gtc aac	1580
	Asn Tyr Ser Ile Val Asp Phe Leu Ile Thr Ala Gly Ala Asn Val Asn	
	195 200 205 210	
20	tcc ccc gac agc cac ggc tgg aca ccc ttg cac tgc gcg gcg tcg tgc	1628
	Ser Pro Asp Ser His Gly Trp Thr Pro Leu His Cys Ala Ala Ser Cys	
	215 220 225	
25	aac gac aca gtc atc tgc atg gcg ctg gtg cag cac ggc gct gca atc	1676
	Asn Asp Thr Val Ile Cys Met Ala Leu Val Gln His Gly Ala Ala Ile	
	230 235 240	
30	ttc gcc acc acg ctc agc gac ggc gcc acc gcc ttc gag aag tgc gac	1724
	Phe Ala Thr Thr Leu Ser Asp Gly Ala Thr Ala Phe Glu Lys Cys Asp	
	245 250 255	
35	cct tac cgc gag ggt tat gct gac tgc gcc acc tac ctg gca gac gtc	1772
	Pro Tyr Arg Glu Gly Tyr Ala Asp Cys Ala Thr Tyr Leu Ala Asp Val	
	260 265 270	
40	gag cag agt atg ggg ctg atg aac agc ggg gca gtg tac gct ctc tgg	1820
	Glu Gln Ser Met Gly Leu Met Asn Ser Gly Ala Val Tyr Ala Leu Trp	
	275 280 285 290	
45	gac tac agc gcc gag ttc ggg gac gag ctg tcc ttc cgc gag ggc gag	1868
	Asp Tyr Ser Ala Glu Phe Gly Asp Glu Leu Ser Phe Arg Glu Gly Glu	
	295 300 305	
50	tcg gtc acc gtg ctg cgg agg gac ggg ccg gag gag acc gac tgg tgg	1916
	Ser Val Thr Val Leu Arg Arg Asp Gly Pro Glu Glu Thr Asp Trp Trp	
	310 315 320	
55	tgg gcc gcg ctg cac ggc cag gag ggc tac gtg ccg cgg aac tac ttc	1964

EP 1 146 054 A1

Trp Ala Ala Leu His Gly Gln Glu Gly Tyr Val Pro Arg Asn Tyr Phe

5 325 330 335

ggg ctg ttc ccc agg gtg aag cct caa agg agt aaa gtc tagcaggata 2013

Gly Leu Phe Pro Arg Val Lys Pro Gln Arg Ser Lys Val

10 340 345 350

gaaggagggtt tctgaggctg acagaaacaa gcattcctgc cttccctcca gacctctccc 2073

tctgtttttt gctgccttta tctgcacccc tcacctgct ggtggtggtc cttgccaccg 2133

15 gttctctgtt ctctggaag tccagggaag aaggagggcc ccagccttaa atttagtaat 2193

ctgccttagc cttgggaggt ctgggaaggg ctggaaatca ctggggacag gaaaccactt 2253

ccttttgcca aatcagatcc cgtccaaagt gcctcccatg cctaccacca tcatcacatc 2313

20 cccagcaag ccagccacct gccagccgg gcctgggatg ggccaccaca ccactggata 2373

ttcctgggag tactgctga caccatctct cccagcagtc ttggggtctg ggtgggaaac 2433

attggtctct accaggatcc ctgccccacc tctccccaat taagtgcctt cacacagcac 2493

25 tggtttaatg ttataaaca aatagagaa actttcctta taaataaaag tagtttgcac 2553

agaaaaaaaa aaacacacaac cttcggccgc cccaccaagc tctgtctcca aaaaaaaaaa 2613

aaaaaaaaa aaaactcgag agttcta 2640

30

<210> 5

<211> 27

35 <212> DNA

<213> Artificial Sequence

40

<220>

<223> Forward primer containing BamHI restriction site

45

<400> 5

ggcggatccc tccgcctgcc gcctgtc

50

<210> 6

<211> 27

<212> DNA

<213> Artificial Sequence

55

EP 1 146 054 A1

<220>

5 <223> Reverse primer containing BamHI restriction site

<400> 6

10 gctggatccg gggcaggggc tggagcc

<210> 7

15 <211> 30

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Forward primer containing SalI restriction site

25

<400> 7

caatggtcga catggatctg actcttgctg

30

<210> 8

<211> 30

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Reverse primer containing BamHI restriction site

40

<400> 8

gatcaggatc ctcaggccaa gtcctttgt

45

<210> 9

<211> 27

<212> DNA

<213> Artificial Sequence

50

55

<220>

EP 1 146 054 A1

<223> Forward primer F132 containing EcoRI restriction site

5

<400> 9

gcttcgaatt ctgtgctgcg gaaggcg

10

<210> 10

<211> 30

15

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Reverse primer F132 containing BamHI restriction site

25

<400> 10

gatcaggatc ctcaggccaa gctcctttgt

30

<210> 11

<211> 22

<212> DNA

35

<213> Artificial sequence

40

<220>

<223> Oct- consensus sequence of kB sequence

45

<400> 11

tgtcgaatgc aaatcactag aa

50

Claims

- 55
1. A polypeptide that comprising an amino acid sequence shown in SEQ ID NO. 1 in substantially purified form, homologue thereof, fragment thereof or homologue of the fragment.
 2. A polypeptide according to claim 1 that comprising an amino acid sequence shown in SEQ ID NO. 1.

EP 1 146 054 A1

3. The RelA-associated inhibitor comprising the polypeptide according to claim 1.
4. A cDNA encoding the polypeptide according to claim 3.
- 5 5. A cDNA according to claim 4 that comprising a nucleotide sequence shown in SEQ ID NO. 2 or a fragment capable of hybridizing selectively to the sequence.
6. A cDNA according to claim 4 that comprising a nucleotide sequence shown in SEQ ID NO. 3 or a fragment capable of hybridizing selectively to the sequence.
- 10 7. A replication or expression vector carrying the cDNA according to any one of claims 4 to 6.
8. A host cell transformed with the replication or expression vector according to claim 7.
- 15 9. A method for producing the polypeptide according to any one of claims 1 to 3 which comprises culturing a host cell according to claim 8 under a condition effective to express the said polypeptide.
10. A monoclonal or polyclonal antibody against the polypeptide according to any one of claims 1 to 3.
- 20 11. A pharmaceutical composition comprising the polypeptide according to any one of claims 1 to 3, the antibody according to claim 9 or antisense thereof, in association with pharmaceutically acceptable diluent and/or carrier.
12. A method for diagnosis of adult respiratory distress syndrome, asthma, Allograft rejection, inflammatory diseases, ischemic diseases, autoimmune diseases including chronic rheumatism, metastasis and invasion of cancer, va-
25 soreconstriction and diseases induced by NFκB besides the above diseases which is **characterized by** determin-
ing the RelA-associated inhibitor activity of the polypeptide according to any one of claims 1 to 3.
13. A method for diagnosis of adult respiratory distress syndrome, asthma, Allograft rejection, inflammatory diseases
(inflammatory arthritis, angitis etc.), ischemic diseases, autoimmune diseases including chronic rheumatism, me-
30 tastasis and invasion of cancer, vasorestriction and diseases induced by NFκB besides the above diseases
which is **characterized by** using the antibody according to claim 10.

FIG. 1




FIG. 2





FIG. 3



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/06753

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl.⁷ C07K 14/47, C12N 15/12, C12N 5/10, C12P 21/02, C07K 16/18, C12P 21/08
 //(C12N 15/12, C12R 1:91), (C12N 5/10, C12R 1:91), (C12P 21/02, C12R
 1:91)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl.⁷ C07K 14/00-16/46, C12N 15/00-90, C12N 1/00-5/28, C12P 21/00-08

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 MEDLINE (STN), Genbank/EMBL/DDBJ/GeneSeq, WPI (DIALOG), BIOSIS (DIALOG)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX PY	Takashi Okamoto et al., "Identification of a novel inhibitor of nuclear factor-kB, RelA-associated inhibitor", J.Biol.Chem. (May 1999), Vol.274, No.22, p.15662-15670	1-9 10, 11
X Y	Lamerdin JE. et al., "Sequence analysis of the ERCC2 gene region in human, mouse, and hamster reveals three linked genes", Genomics (1996), Vol.34, No.3, p.399-409	5, 6 7, 8
A	Ruben SM. et al., "Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B", Science (1991), Vol.251, No.5000, p.1490-1493	1-11
A	Svetlana Gorina et al., "Structure of the p53 tumor suppressor bound to the Ankyrin and SH3 domains of 53BP2", Science (1996), Vol.274, No.5289, p.1001-1005	1-11

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
 29 February, 2000 (29.02.00)

Date of mailing of the international search report
 21 March, 2000 (21.03.00)

Name and mailing address of the ISA/
 Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/06753

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12,13
because they relate to subject matter not required to be searched by this Authority, namely:
The subject matter of claims 12 and 13 relates to a method for diagnosis of the human body.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (I)) (July 1992)